eFT-508 is a selective inhibitor of MNK1 and MNK2 kinases, which play a key role in regulating protein synthesis in cancer cells through phosphorylation of the eukaryotic initiation factor 4E (eIF4E). By blocking this pathway, eFT-508 reduces the expression of oncoproteins such as c-Myc, cyclin D1, and Bcl-2, which are involved in tumor growth and survival. It is primarily investigated for its potential in cancer immunotherapy, where it enhances anti-tumor immune responses by increasing the production of pro-inflammatory cytokines and improving T-cell function. eFT-508 has shown synergistic effects when combined with immune checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 antibodies in preclinical models, making it a promising candidate for combination therapies in solid tumors and hematologic malignancies. Its application is focused on advancing treatments for cancers resistant to current immunotherapies.